← Leaderboards

Daniel R Kuritzkes

Brigham And Women'S Hospital

Google Scholar ↗PubMed ↗ORCID ↗

$313,891,104

Attributed

$470,160,782

Total exposure

26

Grants

15

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $68.3M · FY2005–25

$100M$75M$50M$25M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$470,160,782 · 26

By mechanism

UM1$367,637,380 · 3

U01$79,497,296 · 7

R01$9,249,513 · 4

T32$4,756,812 · 1

R37$4,377,517 · 1

M01$1,624,906 · 6

Top collaborators

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Kenneth H Mayer$64,411,257
Sophia Koo$15,534,982
Serena Patricia Koenig$7,375,882

Others in their field

Top investigators on “Hiv-1”

Barton F Haynes · Duke University$476,288,740
Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
Constance Ann Benson · University Of California, San Diego$272,046,180
Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502

Research focus

Hiv-1Clinical ResearchViralInfectionAids Clinical Trial GroupClinical TrialsHiv InfectionsPreventBaseResearch PersonnelPlasmaPharmaceutical PreparationsAcquired Immunodeficiency SyndromeResponseAntiretroviral TherapyCollaborationsMonitorWomanHospitalsAffectAnti-Retroviral AgentsCellsImmuneResources

Grant awards (141)

Boston HIV CTU$4,506,411

UM1 · FY2025 · AI · contact PI

A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana$1,311,671

U01 · FY2025 · AI

A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana$889,638

U01 · FY2025 · AI

HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy$791,766

R01 · FY2025 · AI

Multidisciplinary HIV Training Program$472,274

T32 · FY2025 · AI · contact PI

Boston HIV CTU$3,541,665

UM1 · FY2024 · AI · contact PI

A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana$2,095,803

U01 · FY2024 · AI

A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$951,356

U01 · FY2024 · AI

HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy$791,766

R01 · FY2024 · AI

Multidisciplinary AIDS Training Program$449,938

T32 · FY2024 · AI · contact PI

Viral Infection and Inflammation Workshop 2024$7,000

R13 · FY2024 · AI · contact PI

Boston HIV CTU$4,338,234

UM1 · FY2023 · AI · contact PI

A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana$1,799,067

U01 · FY2023 · AI

A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$993,747

U01 · FY2023 · AI

HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy$791,766

R01 · FY2023 · AI

Multidisciplinary AIDS Training Program$423,072

T32 · FY2023 · AI · contact PI

Boston HIV CTU$4,700,628

UM1 · FY2022 · AI · contact PI

A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$1,395,641

U01 · FY2022 · AI

HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy$811,645

R01 · FY2022 · AI

Multidisciplinary AIDS Training Program$416,312

T32 · FY2022 · AI · contact PI

Boston HIV CTU$4,358,930

UM1 · FY2021 · AI · contact PI

A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$1,999,002

U01 · FY2021 · AI

HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy$821,589

R01 · FY2021 · AI

Multidisciplinary AIDS Training Program$420,102

T32 · FY2021 · AI · contact PI

Boston HIV CTU$1

UM1 · FY2021 · AI · contact PI

Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)$5,624,553

UM1 · FY2020 · AI

A Pilot Clinical Trial for HIV-1 Eradication$2,373,615

U01 · FY2020 · AI

A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$1,848,151

U01 · FY2020 · AI

Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)$900,000

UM1 · FY2020 · AI

Multidisciplinary AIDS Training Program$338,421

T32 · FY2020 · AI · contact PI

Early Infant Treatment$249,815

U01 · FY2020 · AI

Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)$6,259,351

UM1 · FY2019 · AI

A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$2,158,015

U01 · FY2019 · AI

A Pilot Clinical Trial for HIV-1 Eradication$2,147,412

U01 · FY2019 · AI

Multidisciplinary AIDS Training Program$349,217

T32 · FY2019 · AI · contact PI

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$60,609,395

UM1 · FY2018 · AI · contact PI

Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)$3,085,778

UM1 · FY2018 · AI

A Pilot Clinical Trial for HIV-1 Eradication$2,150,987

U01 · FY2018 · AI

A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana$1,077,403

U01 · FY2018 · AI

Early Infant Treatment$979,999

U01 · FY2018 · AI

Multidisciplinary AIDS Training Program$349,487

T32 · FY2018 · AI · contact PI

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$56,989,695

UM1 · FY2017 · AI · contact PI

Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)$3,046,726

UM1 · FY2017 · AI

Early Infant Treatment$980,000

U01 · FY2017 · AI

Multidisciplinary AIDS Training Program$327,935

T32 · FY2017 · AI · contact PI

Antiretroviral drug resistance in KwaZulu Natal$221,602

R01 · FY2017 · AI · contact PI

Multidisciplinary AIDS Training Program$683

T32 · FY2017 · AI · contact PI

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$35,812,481

UM1 · FY2016 · AI · contact PI

Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)$3,054,663

UM1 · FY2016 · AI

A Pilot Clinical Trial for HIV-1 Eradication$2,139,888

U01 · FY2016 · AI

Early Infant Treatment$979,999

U01 · FY2016 · AI

Antiretroviral drug resistance in KwaZulu Natal$554,533

R01 · FY2016 · AI · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$444,500

R37 · FY2016 · AI · contact PI

Multidisciplinary AIDS Training Program$114,617

T32 · FY2016 · AI · contact PI

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$46,918,193

UM1 · FY2015 · AI · contact PI

Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)$2,781,833

UM1 · FY2015 · AI

A Pilot Clinical Trial for HIV-1 Eradication$1,908,495

U01 · FY2015 · AI

Early Infant Treatment$934,543

U01 · FY2015 · AI

Antiretroviral drug resistance in KwaZulu Natal$567,366

R01 · FY2015 · AI · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$444,500

R37 · FY2015 · AI · contact PI

Multidisciplinary AIDS Training Program$340,895

T32 · FY2015 · AI · contact PI

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$35,170,256

UM1 · FY2014 · AI · contact PI

Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)$3,756,870

UM1 · FY2014 · AI

Early Infant Treatment$979,999

U01 · FY2014 · AI

Antiretroviral drug resistance in KwaZulu Natal$474,296

R01 · FY2014 · AI · contact PI

Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU$455,841

UM1 · FY2014 · AI · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$444,500

R37 · FY2014 · AI · contact PI

Multidisciplinary AIDS Training Grant$331,522

T32 · FY2014 · AI · contact PI

AIDS Clinical Trials Group Network$16,497,033

UM1 · FY2013 · AI · contact PI

Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU$2,290,646

UM1 · FY2013 · AI · contact PI

Antiretroviral drug resistance in KwaZulu Natal$516,543

R01 · FY2013 · AI · contact PI

Multidisciplinary AIDS Training Grant$422,337

T32 · FY2013 · AI · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$417,830

R37 · FY2013 · AI · contact PI

AIDS Clinical Trials Group Network$33,583,843

UM1 · FY2012 · AI · contact PI

Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU$3,226,409

UM1 · FY2012 · AI · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$464,125

R37 · FY2012 · AI · contact PI

AIDS Clinical Trials Group Network$26,127,945

UM1 · FY2011 · AI · contact PI

Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU$3,249,397

U01 · FY2011 · AI · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$417,282

R37 · FY2011 · AI · contact PI

AIDS Clinical Trials Group Network$24,865,379

U01 · FY2010 · AI · contact PI

Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU$3,027,841

U01 · FY2010 · AI · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$421,497

R37 · FY2010 · AI · contact PI

AIDS Clinical Trials Group Network$331,351

U01 · FY2010 · AI · contact PI

V3 loop characterization by ultradeep sequencing during CCR5 antagonist therapy$222,500

R21 · FY2010 · AI · contact PI

HIV-1 Therapeutics and Drug Resistance$116,619

K24 · FY2010 · RR · contact PI

Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU$3,132,349

U01 · FY2009 · AI · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$425,754

R37 · FY2009 · AI · contact PI

V3 loop characterization by ultradeep sequencing during CCR5 antagonist therapy$266,000

R21 · FY2009 · AI · contact PI

HIV-1 Therapeutics and Drug Resistance$116,619

K24 · FY2009 · RR · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$37,775

R37 · FY2009 · AI · contact PI

Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU$3,009,817

U01 · FY2008 · AI · contact PI

Core--Molecular Virology and Molecular Biology Facility$506,414

P30 · FY2008 · AI · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$425,754

R37 · FY2008 · AI · contact PI

HIV-1 Therapeutics and Drug Resistance$116,619

K24 · FY2008 · RR · contact PI

Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU$3,014,456

U01 · FY2007 · AI · contact PI

Core--Molecular Virology and Molecular Biology Facility$492,941

P30 · FY2007 · AI · contact PI

HIV-1 Resistance to Chemokine Receptor Antagonists$434,000

R37 · FY2007 · AI · contact PI

HIV-1 Therapeutics and Drug Resistance$116,619

K24 · FY2007 · RR · contact PI

AIDS CLINICAL TRIALS UNIT$1,516,319

U01 · FY2006 · AI · contact PI

Core--Molecular Virology/Biology Facility$478,797

P30 · FY2006 · AI · contact PI

Fitness of Enfuvirtide-(T-20)-Resistant HIV-1$337,869

R01 · FY2006 · AI · contact PI

HIV-1 Therapeutics and Drug Resistance$116,619

K24 · FY2006 · RR · contact PI

A PHASE IV STUDY OF ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS$2,294

M01 · FY2006 · RR · contact PI

AIDS CLINICAL TRIALS UNIT$1,743,572

U01 · FY2005 · AI

Fitness of Enfuvirtide-(T-20)-Resistant HIV-1$346,000

R01 · FY2005 · AI

HIV-1 THERAPEUTICS AND DRUG RESISTANCE$97,754

K24 · FY2005 · RR

AIDS CLINICAL TRIALS UNIT$1,637,646

U01 · FY2004 · AI

HIV-1 resistance to nucleoside analogues$374,340

R01 · FY2004 · AI

Fitness of Enfuvirtide-(T-20)-Resistant HIV-1$346,000

R01 · FY2004 · AI

HIV-1 THERAPEUTICS AND DRUG RESISTANCE$94,992

K24 · FY2004 · RR

AIDS CLINICAL TRIALS UNIT$1,624,923

U01 · FY2003 · AI

HIV-1 resistance to nucleoside analogues$374,774

R01 · FY2003 · AI

Fitness of Enfuvirtide-(T-20)-Resistant HIV-1$173,000

R01 · FY2003 · AI

HIV-1 THERAPEUTICS AND DRUG RESISTANCE$92,376

K24 · FY2003 · RR

HIV-1 resistance to nucleoside analogues$375,195

R01 · FY2002 · AI

ACTG370 LAMIVUDINE VS DELAVIRDINE IN 3TC EXPERIENCED SUBJECTS$190,747

M01 · FY2002 · RR

PHASE I TRIAL OF T-1249 IN HIV INFECTED ADULTS$190,747

M01 · FY2002 · RR

VIRACEPT AND SUSTIVA FOR TREATMENT OF HIV-1$190,747

M01 · FY2002 · RR

ACTG364 EFFICACY OF NELFINAVIR AND/OR DMP 266 WITH NUCLEOSIDE ANALOGS$190,747

M01 · FY2002 · RR

HIV-1 THERAPEUTICS AND DRUG RESISTANCE$89,466

K24 · FY2002 · RR

HIV-1 resistance to nucleoside analogues$305,775

R01 · FY2001 · AI

ACTG370 LAMIVUDINE VS DELAVIRDINE IN 3TC EXPERIENCED SUBJECTS$190,747

M01 · FY2001 · RR

PHASE I TRIAL OF T-1249 IN HIV INFECTED ADULTS$190,747

M01 · FY2001 · RR

ACTG364 EFFICACY OF NELFINAVIR AND/OR DMP 266 WITH NUCLEOSIDE ANALOGS$190,747

M01 · FY2001 · RR

VIRACEPT AND SUSTIVA FOR TREATMENT OF HIV-1$190,747

M01 · FY2001 · RR

HIV-1 THERAPEUTICS AND DRUG RESISTANCE$86,023

K24 · FY2001 · RR

VIRACEPT AND SUSTIVA FOR TREATMENT OF HIV-1$0

M01 · FY2001 · RR

ACTG370 LAMIVUDINE VS DELAVIRDINE IN 3TC EXPERIENCED SUBJECTS$0

M01 · FY2001 · RR

ACTG364 EFFICACY OF NELFINAVIR AND/OR DMP 266 WITH NUCLEOSIDE ANALOGS$0

M01 · FY2001 · RR

PHASE I TRIAL OF T-1249 IN HIV INFECTED ADULTS$0

M01 · FY2001 · RR

HIV-1 DUAL RESISTANCE TO AZT AND 3TC$273,688

R01 · FY2000 · AI

ACTG364 EFFICACY OF NELFINAVIR AND/OR DMP 266 WITH NUCLEOSIDE ANALOGS$32,212

M01 · FY2000 · RR

PNU 140690 DOSE ESCALATION--EVAL TOLERANCE PHARMACOKINETICS EFF IN HIV$32,212

M01 · FY2000 · RR

ACTG370 LAMIVUDINE VS DELAVIRDINE IN 3TC EXPERIENCED SUBJECTS$32,212

M01 · FY2000 · RR

VIRACEPT AND SUSTIVA FOR TREATMENT OF HIV-1$0

M01 · FY2000 · RR

VIRACEPT AND SUSTIVA FOR TREATMENT OF HIV-1$0

M01 · FY2000 · RR

ACTG370 LAMIVUDINE VS DELAVIRDINE IN 3TC EXPERIENCED SUBJECTS$0

M01 · FY2000 · RR

PNU 140690 DOSE ESCALATION--EVAL TOLERANCE PHARMACOKINETICS EFF IN HIV$0

M01 · FY2000 · RR

ACTG364 EFFICACY OF NELFINAVIR AND/OR DMP 266 WITH NUCLEOSIDE ANALOGS$0

M01 · FY2000 · RR

PHASE I TRIAL OF T-1249 IN HIV INFECTED ADULTS$0

M01 · FY2000 · RR

PHASE I TRIAL OF T-1249 IN HIV INFECTED ADULTS$0

M01 · FY2000 · RR